PCI Pharma Services, a Philadelphia, Pennsylvania-based CDMO of drug products and a provider of contract packaging services, is investing more than $365 million in new and expanded facilities in Europe and North America to support clinical and commercial-scale final assembly and packaging of drug-device combination products using advanced drug delivery systems, with an emphasis on injectable formats. 

In the US, PCI has plans for a 545,000-square-foot expansion at its campus in Rockford, Illinois, for advanced drug delivery and drug-device combination assembly and packaging. The expansion consists of a 475,000-square-foot project comprising 345,000 square feet for advanced drug-delivery injectable packaging and 130,000 square feet of additional warehousing for products in all development phases. The space houses over 20 customer suites, with scalable technology for the clinical and commercial-scale final assembly and packaging of vials, prefilled syringes, autoinjectors, and pen-cartridge combinations, with top-open cartoning technology and final assembly and functional product testing to ISO standards. 

Also in the US, PCI is planning a further 70,000-square-foot expansion for advanced drug delivery and drug-device combination assembly and packaging. The facility will support a range of low- to high-speed packaging technologies for a variety of advanced drug-delivery categories, including but not limited to vials, prefilled syringes, autoinjectors, and on-body injectors. The plant is planned to be brought on line in two phases, with operations expected to begin in the third quarter of 2025. 

In Europe, PCI is moving forward with a newly acquired pharmaceutical packaging and device assembly facility near Dublin, Ireland, to provide large-scale temperature-controlled storage capabilities. Operations are scheduled to begin in the fourth quarter of 2024, with the facility providing commercial-scale packaging and assembly operations for injectables as well as oral solid-dose drug products. 

Elsewhere in Ireland, PCI has broken ground on a new packaging and device-assembly services facility at its CityNorth Dublin campus. Slated to begin operations in the third quarter of 2025, the plant will provide increased capacity for the final assembly, labeling, and packaging of injectable drug products, including vials, prefilled syringes, and drug-device combination products such as autoinjectors. The facility also will include cold-chain packaging for injectable and biologic products as well as associated temperature-controlled storage. 
 
Source: PCI Pharma